Plain-English translation of NCT06657157 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is watching for a specific side effect called peripheral neuropathy (nerve damage in the hands and feet) in patients with advanced bladder cancer who are being treated with enfortumab vedotin and pembrolizumab. Researchers want to understand how often this side effect happens, how severe it becomes, and how it affects patients' quality of life and ability to continue treatment.
While these two immunotherapy drugs have shown promise in treating advanced bladder cancer, doctors need to better understand the nerve damage side effect that can occur—how common it is, when it happens, and what impact it has on patients so they can prepare for it and manage it more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive the two immunotherapy medications as part of your regular cancer treatment at one of two German university hospitals. During your treatment visits, researchers would carefully monitor you for signs of nerve damage through examinations and questionnaires about how the side effects are affecting your daily activities, work, and quality of life. The study simply observes and documents what happens during your standard cancer care rather than adding new or experimental procedures.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Germany